中华临床免疫和变态反应杂志2016，Vol.10Issue(4)：334-339,6.DOI:10.3969/j.issn.1673-8705.2016.04.004
别嘌醇及非布司他治疗中国痛风患者的成本效果
Cost-effectiveness of Allopurinol and Febuxostat in the Treatment of Chinese Patients with Gout
摘要
Abstract
Objective To assess and compare the cost-effectiveness of urate-lowering treatment strategies based on allopurinol and febuxostat in Chinese patients with gout .Methods Target population was Chinese adult pa-tients with gout .The study was done from a healthcare care provider's perspective .A decision-tree model was constructed to analyze and compare the costs and clinical outcomes of three urate-lowering treatment strategies . The three strategies were (1) allopurinol 300 mg for 6 months, if the target serum uric acid level of less than 360μmol/L was not achieved , then patients switched to febuxostat 40 mg and 80 mg sequentially;(2) febux-ostat 40 mg for 6 months, if the target level was not achieved , then it was followed by febuxostat 80 mg for 6 months;(3) no treatment.The main outcome measures were quality-adjusted life-years (QALYs) and incre-mental cost-effectiveness ratios ( ICER ) .Sensitivity analysis was conducted by using Tornado analysis . Results The simulated results showed that febuxostat as the first line choice strategy was dominated by allo-purinol-febuxostat sequential treatment strategy .The gained QALY were similar for the two strategies (1.61 vs.1.61), however, the costs were much lower when allopurinol-febuxostat sequential treatment strategy was chosen (￥10 098 vs.￥21 446).Conclusion Allopurinol-febuxostat sequential treatment strategy may be more cost-effective than febuxostat as the first line choice for the management of gout in China mainland .关键词
别嘌醇/非布司他/成本效果分析/质量调整生命年Key words
allopurinol/febuxostat/cost-effectiveness/quality-adjusted life-years分类
医药卫生引用本文复制引用
焦洋,方卫纲,曾学军..别嘌醇及非布司他治疗中国痛风患者的成本效果[J].中华临床免疫和变态反应杂志,2016,10(4):334-339,6.基金项目
国家卫计委公益性行业科研专项 （）
